GNCC Capital, Inc. (GNCP) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $8.71M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGNCC Capital, Inc. (GNCP) trades at $0.00005. GNCC Capital, Inc., through its subsidiary, focuses on producing and selling cannabis CBD pharmaceutical grade oils. Market cap: $8.71M, Sector: Basic materials.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GNCP: GNCP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNCP against Basic Materials peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
GNCP: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
GNCC Capital, Inc. (GNCP) Materials & Commodity Exposure
GNCC Capital, Inc. operates in the basic materials sector, specifically focusing on the production and distribution of cannabis CBD pharmaceutical grade oils in Colombia and Latin America. The company faces significant competition and regulatory hurdles in the evolving cannabis market.
What Is the Investment Thesis for GNCP?
GNCC Capital, Inc. presents a speculative investment opportunity within the cannabis CBD pharmaceutical sector in Latin America. The company's focus on pharmaceutical-grade CBD oils positions it to potentially capture a segment of the market demanding high-quality products. However, the company's small market capitalization of $8.71M and negative beta of -38.68 indicate high volatility and sensitivity to market movements. Growth depends on successful navigation of regulatory hurdles, securing distribution partnerships, and scaling production efficiently. Investors should carefully consider the risks associated with investing in a micro-cap company operating in a rapidly evolving and highly regulated industry.
Based on FMP financials and quantitative analysis
GNCP Key Highlights
GNCC Capital, Inc. operates in the cannabis CBD pharmaceutical sector through its subsidiary BioCann Pharma S.A.S.
- The company focuses on producing and selling cannabis CBD pharmaceutical grade oils.
- GNCC Capital distributes its products through channels in Colombia and throughout Latin America.
- The company is based in Las Vegas, Nevada.
- GNCC Capital has a market capitalization of $8.71M.
Who Are GNCP's Competitors?
GNCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CGDNF Conroy Gold and Natural Resources PLC | $0.14 | 0.00% | $10.8M | 519-signal |
| OSCI Osceola Gold, Inc. | $0.07 | +88.68% | $27.2M | 489-signal |
| CGLCF Cassiar Gold Corp. | $0.33 | -2.50% | $53.6M | 489-signal |
| AMQFF Abitibi Metals Corp. | $0.55 | -1.24% | $64.4M | 489-signal |
| NAMM Namib Minerals | $1.33 | -3.26% | $72.7M | 615-pillar |
| MLMLF McFarlane Lake Mining Limited | $0.38 | -3.99% | $104M | 489-signal |
| MGMLF Maple Gold Mines Ltd. | $2.05 | -3.76% | $152M | 509-signal |
| AUMBF 1911 Gold Corporation | $0.58 | -5.24% | $180M | 489-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are GNCP's Key Strengths?
Focus on pharmaceutical-grade CBD oils.
- Distribution network in Colombia and Latin America.
- Potential for growth in the expanding cannabis market.
- Expertise in cannabis cultivation and processing.
What Are GNCP's Weaknesses?
Small market capitalization.
- Dependence on a single subsidiary.
- Limited product diversification.
- Negative beta indicating high volatility.
What Could Drive GNCP Stock Higher?
Potential regulatory changes in Latin American countries regarding cannabis legalization.
- Increasing acceptance of CBD products for medical use.
- Expansion of distribution network in Latin America.
What Are the Key Risks for GNCP?
Regulatory setbacks in the cannabis industry.
- Intense competition from established pharmaceutical companies.
- Fluctuations in the price of cannabis and CBD.
- Dependence on a single subsidiary for revenue generation.
- Negative beta indicating high volatility.
What Are the Growth Opportunities for GNCP?
- Expansion into New Latin American Markets: GNCC Capital can expand its distribution network to other Latin American countries, capitalizing on the increasing acceptance of CBD products in the region. The Latin American cannabis market is projected to experience significant growth, offering opportunities for GNCC Capital to increase its market share and revenue. Timeline: Within the next 3-5 years.
- Development of New CBD Products: GNCC Capital can invest in research and development to create new CBD-based pharmaceutical products, catering to specific medical conditions and patient needs. This diversification can enhance the company's product portfolio and attract a wider customer base. The global CBD market is expected to continue expanding, driven by increasing awareness of its potential health benefits. Timeline: Ongoing.
- Strategic Partnerships with Pharmaceutical Companies: GNCC Capital can form strategic alliances with established pharmaceutical companies to co-develop and distribute its CBD products. These partnerships can provide access to established distribution channels, regulatory expertise, and marketing resources, accelerating market penetration. The pharmaceutical industry is increasingly exploring the potential of cannabis-based therapies. Timeline: Within the next 2-3 years.
- Vertical Integration of Supply Chain: GNCC Capital can integrate its supply chain by acquiring or establishing its own cultivation and processing facilities. This vertical integration can improve quality control, reduce costs, and ensure a consistent supply of raw materials. The cannabis industry is increasingly emphasizing the importance of supply chain management. Timeline: Ongoing.
- Focus on Pharmaceutical-Grade Quality: By maintaining a strict focus on producing pharmaceutical-grade CBD oils, GNCC Capital can differentiate itself from competitors and attract customers seeking high-quality products. The pharmaceutical sector demands rigorous quality standards, providing a barrier to entry for less sophisticated producers. Timeline: Ongoing.
What Are GNCP's Competitive Advantages?
- Focus on pharmaceutical-grade CBD oil production.
- Established distribution channels in Colombia and Latin America.
- Expertise in navigating the regulatory landscape of the cannabis industry.
- Potential for brand recognition and customer loyalty through consistent product quality.
What Does GNCP Do?
GNCC Capital, Inc., based in Las Vegas, Nevada, operates through its subsidiary, BioCann Pharma S.A.S., to produce and distribute cannabis CBD pharmaceutical grade oils. The company focuses on serving the Latin American market, primarily Colombia, through established distribution channels. GNCC Capital aims to capitalize on the growing demand for CBD products in the pharmaceutical sector within the region. The company's business model centers around cultivating, processing, and distributing high-quality CBD oils that meet pharmaceutical standards. GNCC Capital navigates the complex regulatory landscape of the cannabis industry in Latin America to ensure compliance and market access. The company's success hinges on its ability to maintain consistent product quality, secure distribution partnerships, and adapt to evolving regulations in the cannabis market.
What Products and Services Does GNCP Offer?
- Produces cannabis CBD pharmaceutical grade oils.
- Sells products through distribution channels.
- Operates primarily in Colombia and throughout Latin America.
- Focuses on the pharmaceutical sector.
- Cultivates and processes CBD oils.
- Navigates the regulatory landscape of the cannabis industry.
How Does GNCP Make Money?
- Cultivation and processing of cannabis plants to extract CBD oil.
- Manufacturing of pharmaceutical-grade CBD oil products.
- Distribution of products through established channels in Colombia and Latin America.
- Revenue generation through the sale of CBD oil products to distributors and end-users.
What Industry Does GNCP Operate In?
GNCC Capital, Inc. operates within the evolving cannabis industry, specifically targeting the CBD pharmaceutical sector in Latin America. The global cannabis market is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. However, the industry faces challenges such as regulatory uncertainty, intense competition, and varying consumer preferences. GNCC Capital's success depends on its ability to navigate these challenges and establish a strong presence in its target markets. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers.
Who Are GNCP's Key Customers?
- Pharmaceutical companies seeking high-quality CBD ingredients.
- Distributors of pharmaceutical products in Colombia and Latin America.
- Patients seeking CBD-based treatments for various medical conditions.
- Retailers of health and wellness products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 48 |
| 2026-08-26 | 48 |
| 2026-08-29 | 48 |
| 2026-09-01 | 48 |
| 2026-09-04 | 48 |
| 2026-09-07 | 48 |
| 2026-09-10 | 48 |
What changed?
The score has stayed at 48.
Over the same 18 days the stock moved +0.0%.
Company Profile
GNCC Capital, Inc. operates in the Gold industry within the Basic Materials sector. It is headquartered in Las Vegas, US. The company is led by CEO Nicolaas Edward Blom. GNCP has traded publicly since 2009.
GNCP Valuation & Market Position
With a $8.71M market cap, GNCC Capital, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for GNCC Capital, Inc. stands at 357.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.5%, showing how much profit it generates from its asset base. A current ratio of 9.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.
GNCP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on pharmaceutical-grade CBD oils.
- Distribution network in Colombia and Latin America.
- Potential for growth in the expanding cannabis market.
- Expertise in cannabis cultivation and processing.
Bear Case
- Small market capitalization.
- Dependence on a single subsidiary.
- Limited product diversification.
- Negative beta indicating high volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNCP Latest News
No recent news available for GNCP.
GNCP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GNCP.
Price Targets
Wall Street price target analysis for GNCP.
GNCP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for GNCP; grades run from A+ (80-100) to F (below 30).
GNCP OTC Market Information
GNCP trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About GNCP (Basic Materials)
Is GNCP a good stock?
Stock Expert AI does not rate GNCP buy, sell or hold. GNCC Capital, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for GNCP?
GNCC Capital, Inc. faces several risks inherent in the cannabis industry, including regulatory uncertainty, intense competition, and fluctuations in the price of cannabis and CBD.
What are the key factors to evaluate for GNCP?
Evaluate GNCP on fundamentals, analyst consensus, and risk factors. GNCC Capital, Inc. operates in the cannabis CBD pharmaceutical sector through its subsidiary BioCann Pharma S.A.S. Not financial advice.
How frequently does GNCP data refresh on this page?
GNCP's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNCP's recent stock price performance?
GNCC Capital, Inc. (GNCP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on pharmaceutical-grade CBD oils. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNCP overvalued or undervalued right now?
GNCC Capital, Inc. (GNCP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of GNCP?
Yes, most major brokerages offer fractional shares of GNCC Capital, Inc. (GNCP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GNCP's earnings and financial reports?
GNCC Capital, Inc. (GNCP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for GNCP earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.